Mycobiome in the Lower Respiratory Tract – A Clinical Perspective

Robert Krause, Christine Moissl-Eichinger, Bettina Halwachs, Gregor Gorkiewicz, Gabriele Berg, Thomas Valentin, Jürgen Prattes, Christoph Högenauer, Ines Zollner-Schwetz

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Recently the paradigm that the healthy lung is sterile was challenged and it is now believed that the lungs harbor a diverse microbiota also contributing to the pathogenesis of various diseases. Most of the research studies targeting the respiratory microbiome have focused on bacteria and their impact on lung health and lung diseases. Recently, also the mycobiome has gained attention. Lower respiratory tract (LRT) diseases (e.g., cystic fibrosis) and other diseases or conditions (e.g., HIV infection, lung transplantation, and treatment at intensive care units) have been investigated with regard to possible involvement of mycobiome in development or progression of diseases. It has been shown that diversities of mycobiome in the LRT vary in different populations and conditions. It has been proposed that the mycobiome diversity associated with LRT can vary with different stages of diseases. Overall, Candida was the dominant fungal genus in LRT samples. In this review, we summarize the recent findings regarding the human LRT mycobiome from a clinical perspective focussing on characterization of investigated patient groups and healthy controls as well as sampling techniques. From these data, clinical implications for further studies or routine practice are drawn. To obtain clinically relevant answers efforts should be enhanced to collect well characterized and described patient groups as well as healthy individuals for comparative data analysis and to apply thorough sampling techniques. We need to proceed with elucidation of the role of mycobiota in healthy LRT and LRT diseases to hopefully improve patient care.
Original languageEnglish
JournalFrontiers in Microbiology
Volume7
Issue number2169
Publication statusPublished - 2017

Fingerprint

Respiratory System
Respiratory Tract Diseases
Microbiota
Lung
Lung Transplantation
Candida
Cystic Fibrosis
Lung Diseases
HIV Infections
Intensive Care Units
Disease Progression
Patient Care
Mycobiome
Bacteria
Control Groups
Health
Research
Population
Therapeutics

Cite this

Krause, R., Moissl-Eichinger, C., Halwachs, B., Gorkiewicz, G., Berg, G., Valentin, T., ... Zollner-Schwetz, I. (2017). Mycobiome in the Lower Respiratory Tract – A Clinical Perspective. Frontiers in Microbiology , 7(2169).

Mycobiome in the Lower Respiratory Tract – A Clinical Perspective. / Krause, Robert; Moissl-Eichinger, Christine; Halwachs, Bettina; Gorkiewicz, Gregor; Berg, Gabriele; Valentin, Thomas; Prattes, Jürgen; Högenauer, Christoph; Zollner-Schwetz, Ines.

In: Frontiers in Microbiology , Vol. 7, No. 2169, 2017.

Research output: Contribution to journalArticleResearchpeer-review

Krause, R, Moissl-Eichinger, C, Halwachs, B, Gorkiewicz, G, Berg, G, Valentin, T, Prattes, J, Högenauer, C & Zollner-Schwetz, I 2017, 'Mycobiome in the Lower Respiratory Tract – A Clinical Perspective' Frontiers in Microbiology , vol. 7, no. 2169.
Krause, Robert ; Moissl-Eichinger, Christine ; Halwachs, Bettina ; Gorkiewicz, Gregor ; Berg, Gabriele ; Valentin, Thomas ; Prattes, Jürgen ; Högenauer, Christoph ; Zollner-Schwetz, Ines. / Mycobiome in the Lower Respiratory Tract – A Clinical Perspective. In: Frontiers in Microbiology . 2017 ; Vol. 7, No. 2169.
@article{91b90ab755234c4f9b98e45b198f8ca3,
title = "Mycobiome in the Lower Respiratory Tract – A Clinical Perspective",
abstract = "Recently the paradigm that the healthy lung is sterile was challenged and it is now believed that the lungs harbor a diverse microbiota also contributing to the pathogenesis of various diseases. Most of the research studies targeting the respiratory microbiome have focused on bacteria and their impact on lung health and lung diseases. Recently, also the mycobiome has gained attention. Lower respiratory tract (LRT) diseases (e.g., cystic fibrosis) and other diseases or conditions (e.g., HIV infection, lung transplantation, and treatment at intensive care units) have been investigated with regard to possible involvement of mycobiome in development or progression of diseases. It has been shown that diversities of mycobiome in the LRT vary in different populations and conditions. It has been proposed that the mycobiome diversity associated with LRT can vary with different stages of diseases. Overall, Candida was the dominant fungal genus in LRT samples. In this review, we summarize the recent findings regarding the human LRT mycobiome from a clinical perspective focussing on characterization of investigated patient groups and healthy controls as well as sampling techniques. From these data, clinical implications for further studies or routine practice are drawn. To obtain clinically relevant answers efforts should be enhanced to collect well characterized and described patient groups as well as healthy individuals for comparative data analysis and to apply thorough sampling techniques. We need to proceed with elucidation of the role of mycobiota in healthy LRT and LRT diseases to hopefully improve patient care.",
author = "Robert Krause and Christine Moissl-Eichinger and Bettina Halwachs and Gregor Gorkiewicz and Gabriele Berg and Thomas Valentin and J{\"u}rgen Prattes and Christoph H{\"o}genauer and Ines Zollner-Schwetz",
year = "2017",
language = "English",
volume = "7",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "2169",

}

TY - JOUR

T1 - Mycobiome in the Lower Respiratory Tract – A Clinical Perspective

AU - Krause, Robert

AU - Moissl-Eichinger, Christine

AU - Halwachs, Bettina

AU - Gorkiewicz, Gregor

AU - Berg, Gabriele

AU - Valentin, Thomas

AU - Prattes, Jürgen

AU - Högenauer, Christoph

AU - Zollner-Schwetz, Ines

PY - 2017

Y1 - 2017

N2 - Recently the paradigm that the healthy lung is sterile was challenged and it is now believed that the lungs harbor a diverse microbiota also contributing to the pathogenesis of various diseases. Most of the research studies targeting the respiratory microbiome have focused on bacteria and their impact on lung health and lung diseases. Recently, also the mycobiome has gained attention. Lower respiratory tract (LRT) diseases (e.g., cystic fibrosis) and other diseases or conditions (e.g., HIV infection, lung transplantation, and treatment at intensive care units) have been investigated with regard to possible involvement of mycobiome in development or progression of diseases. It has been shown that diversities of mycobiome in the LRT vary in different populations and conditions. It has been proposed that the mycobiome diversity associated with LRT can vary with different stages of diseases. Overall, Candida was the dominant fungal genus in LRT samples. In this review, we summarize the recent findings regarding the human LRT mycobiome from a clinical perspective focussing on characterization of investigated patient groups and healthy controls as well as sampling techniques. From these data, clinical implications for further studies or routine practice are drawn. To obtain clinically relevant answers efforts should be enhanced to collect well characterized and described patient groups as well as healthy individuals for comparative data analysis and to apply thorough sampling techniques. We need to proceed with elucidation of the role of mycobiota in healthy LRT and LRT diseases to hopefully improve patient care.

AB - Recently the paradigm that the healthy lung is sterile was challenged and it is now believed that the lungs harbor a diverse microbiota also contributing to the pathogenesis of various diseases. Most of the research studies targeting the respiratory microbiome have focused on bacteria and their impact on lung health and lung diseases. Recently, also the mycobiome has gained attention. Lower respiratory tract (LRT) diseases (e.g., cystic fibrosis) and other diseases or conditions (e.g., HIV infection, lung transplantation, and treatment at intensive care units) have been investigated with regard to possible involvement of mycobiome in development or progression of diseases. It has been shown that diversities of mycobiome in the LRT vary in different populations and conditions. It has been proposed that the mycobiome diversity associated with LRT can vary with different stages of diseases. Overall, Candida was the dominant fungal genus in LRT samples. In this review, we summarize the recent findings regarding the human LRT mycobiome from a clinical perspective focussing on characterization of investigated patient groups and healthy controls as well as sampling techniques. From these data, clinical implications for further studies or routine practice are drawn. To obtain clinically relevant answers efforts should be enhanced to collect well characterized and described patient groups as well as healthy individuals for comparative data analysis and to apply thorough sampling techniques. We need to proceed with elucidation of the role of mycobiota in healthy LRT and LRT diseases to hopefully improve patient care.

M3 - Article

VL - 7

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - 2169

ER -